MetaVia Inc. 8-K

What Happened
MetaVia Inc. filed an 8-K on June 8, 2026, announcing late-breaking presentations at the American Diabetes Association (ADA) 2026 Scientific Sessions (June 5–8). The company reported interim Phase 1 higher-dose results for DA-1726 (a GLP-1/GCGR dual agonist) from a randomized, double-blind, placebo-controlled multiple-ascending-dose study and preclinical combination data for vanoglipel (DA-1241), a GPR119 agonist. A press release describing the presentations was attached as Exhibit 99.1 to the filing.

Key Details

• DA-1726 (48 mg cohort): generally well tolerated with mainly mild–moderate, transient GI adverse events; no treatment-related discontinuations or serious adverse events reported. Pharmacokinetics showed sustained, dose-proportional exposure.
• Body weight outcomes for DA-1726: −6.1% vs baseline at Day 26 and −9.1% at Day 54 (p<0.05 vs placebo at Day 26); continued reductions through Week 8 with no plateau. Waist circumference fell 5.8 cm (Day 22) and 9.8 cm (Day 54); BMI reductions of 2.3 and 3.4 kg/m² at Day 22 and Day 54.
• Vanoglipel + resmetirom (preclinical MASH model): combo produced a 23.6% body-weight reduction vs control (p<0.05), large decreases in fat mass (−43.5%) and epididymal fat (−42.1%), ALT reduction up to 83.5%, and histologic improvements in liver lipid, inflammation and fibrosis markers.
• Vanoglipel + metformin (preclinical T2D/obesity model): combo reduced non-fasting glucose by 28.7% and fasting glucose by 22.7% vs control (p<0.05), achieved −16.3% body weight vs control (p<0.05), decreased fat mass (−25.6% vs baseline), increased total GLP‑1 (6.4×) and PYY (1.5×), and reduced food intake.

Why It Matters
The DA-1726 Phase 1 higher-dose data show clinically meaningful, statistically significant early weight loss and a tolerability profile that supports continued clinical development for obesity. The vanoglipel preclinical combination results suggest potential therapeutic synergy for MASH, type 2 diabetes and obesity when paired with agents like resmetirom or metformin. For investors, these findings are material progress points for MetaVia’s obesity/metabolic pipeline — DA-1726 is in early human testing (Phase 1) and vanoglipel results are preclinical, so further trials and regulatory steps are required before any commercial or safety conclusions can be drawn.